The Impact of the Entry of Biosimilars: Evidence from Europe
Abstract Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry, however only a few biosimilars have been approved in the US since 2015, thereby largely pres...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Springer US
2021
|
| Online Access: | https://hdl.handle.net/1721.1/131508 |